Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial
Centre for Cancer Biology · The University of Adelaide · +40 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
184
total citations
- FWCI
- 44.50
- Percentile
- 100%
- References
- 23
Citations per year
Authors
111- CJChristopher J. SweeneyCorresponding
Centre for Cancer Biology, The University of Adelaide
- AMAndrew Martin
The University of Sydney, National Health and Medical Research Council
- MRMartin R. Stockler
The University of Sydney, Concord Repatriation General Hospital, Chris O’Brien Lifehouse, National Health and Medical Research Council
- SBStephen Begbie
Port Macquarie Base Hospital
- LCLeanna Cheung
The University of Sydney, National Health and Medical Research Council
Topics & keywords
Topics
Keywords
- Medicine
- Docetaxel
- Enzalutamide
- Clinical endpoint
- Prostate cancer
- Internal medicine
- Antiandrogen
- Population
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.